Tango Therapeutics (TNGX) Change in Account Payables (2020 - 2026)

Tango Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• On a quarterly basis, Change in Account Payables rose 9.51% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was -$670000.0, a 12.42% decrease from a year earlier, with the FY2025 full-year figure at -$825000.0, up 30.32% from the prior year.
• Change in Account Payables rose to $1.8 million in Q1 2026 per TNGX's latest filing, from -$1.2 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $4.5 million in Q3 2022 and bottomed at -$2.8 million in Q2 2024.
• The 5-year median for Change in Account Payables is -$359000.0 (2022), against an average of -$48941.2.
• Across the five-year window, Change in Account Payables jumped 532.31% in 2023 and tumbled 2748.86% in 2024, its largest moves.
• Year by year, Change in Account Payables stood at -$1.0 million in 2022, then surged by 91.54% to -$88000.0 in 2023, then tumbled by 2748.86% to -$2.5 million in 2024, then soared by 50.9% to -$1.2 million in 2025, then surged by 245.0% to $1.8 million in 2026.
• Per Business Quant, the three latest TNGX Change in Account Payables figures stand at $1.8 million (Q1 2026), -$1.2 million (Q4 2025), and -$344000.0 (Q3 2025).